1-4 of 4
Jeffrey A. Ledbetter
Close
Sort by
Journal Articles

Role of CD37 SMIP a Novel Engineered Small Modular Immunopharmaceutical in the Treatment of CLL.

Rosa Lapalombella, PhD, Xiaobin B. Zhao, PhD, Peter R. Baum, PhD, Jeffrey A. Ledbetter, PhD, Natarajan Muthusamy, DVM, PhD, John C. Byrd, MD
Journal: Blood
Blood (2007) 110 (11): 801.
https://doi.org/10.1182/blood.V110.11.801.801
Published: 2007
Journal Articles

CD37−SMIP TM Drug Induced Caspase Independent Cellular Cytotoxicity Is Associated with Activation of Phosphotyrosine-Mediated Signaling Events in Primary Chronic Lymphocytic Leukemia (CLL) B Cells.

Rosa Lapalombella, Xiaobin B. Zhao, Laura Grosmaire, Jeffrey A. Ledbetter, Natarajan Muthusamy, John C. Byrd
Journal: Blood
Blood (2006) 108 (11): 753.
https://doi.org/10.1182/blood.V108.11.753.753
Published: 2006
Journal Articles

Apoptosis of Malignant Human B Cells by Ligation of CD20 With Monoclonal Antibodies

Daming Shan, Jeffrey A. Ledbetter, Oliver W. Press
Journal: Blood
Blood (1998) 91 (5): 1644–1652.
https://doi.org/10.1182/blood.V91.5.1644
Published: 1998
Journal Articles

In Vivo Efficacy and Toxicity of a Single-Chain Immunotoxin Targeted to CD40

Joseph A. Francisco, George J. Schreiber, Chuck R. Comereski, Laurence E. Mezza, Garvin L. Warner, Thomas J. Davidson, Jeffrey A. Ledbetter, Clay B. Siegall
Journal: Blood
Blood (1997) 89 (12): 4493–4500.
https://doi.org/10.1182/blood.V89.12.4493
Published: 1997